| Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer (NCT03983759) | Henan Cancer Hospital | 2019-06-20 |
| Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors (NCT04234113) | SOTIO Biotech AG | 2019-06-13 |
| Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy (NCT04106167) | Fate Therapeutics | 2019-06-11 |
| Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer (NCT03923270) | H. Lee Moffitt Cancer Center and Research Institute | 2019-06-06 |
| Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer (NCT03913455) | Shadia Jalal, MD | 2019-06-06 |
| Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies (NCT03881488) | Compass Therapeutics | 2019-05-17 |
| Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer (NCT04192682) | Changzhou Cancer Hospital of Soochow University | 2019-05-08 |
| A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (NCT03752398) | Xencor, Inc. | 2019-05-01 |
| Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride (NCT03890055) | Chifeng Municipal Hospital | 2019-04-01 |
| The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) (NCT03896958) | SpeciCare | 2019-03-21 |
| DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer (NCT03879798) | Memorial Sloan Kettering Cancer Center | 2019-03-15 |
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (NCT03841110) | Fate Therapeutics | 2019-02-15 |
| A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice (NCT03782207) | Hoffmann-La Roche | 2019-02-07 |
| A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors (NCT03734913) | Guangdong Zhongsheng Pharmaceutical Co., Ltd. | 2019-01-25 |
| Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC (NCT03780283) | First Hospital of Shijiazhuang City | 2019-01-01 |
| Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer (NCT03728361) | Dwight Owen | 2018-12-31 |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (NCT03228667) | ImmunityBio, Inc. | 2018-12-11 |
| Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy (NCT03670056) | Yale University | 2018-12-06 |
| PEG-rhG-CSF in Elderly Patients With Small Cell Lung Cancer Receiving Chemotherapy (NCT03776604) | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | 2018-12-05 |
| A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer (NCT03639194) | AbbVie | 2018-10-24 |
| Neoadjuvant Therapy Combined With Radical Surgery for the Treatment of Small Cell Lung Cancer (SCLC) in II and IIIA Stage (NCT03523234) | Peng Zhang | 2018-10-01 |
| Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer (NCT04731909) | Third Military Medical University | 2018-10-01 |
| Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (NCT03703297) | AstraZeneca | 2018-09-27 |
| A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies (NCT03652077) | Incyte Corporation | 2018-09-24 |
| M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers (NCT03554473) | National Cancer Institute (NCI) | 2018-09-11 |
| A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC (NCT03392064) | Amgen | 2018-09-10 |
| Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer (NCT03651219) | Beijing Chest Hospital | 2018-09-08 |
| Clinical Study of Combined Radical Operation With Postoperative Adjuvant Chemotherapy and Prophylactic Cranial Irradiation in pT1-2N0M0 Stage of Small Cell Lung Cancer (NCT03514849) | Peng Zhang | 2018-08-01 |
| A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer (NCT03532880) | Memorial Sloan Kettering Cancer Center | 2018-07-12 |
| DOTATOC PET/CT for Imaging NET Patients (NCT03583528) | British Columbia Cancer Agency | 2018-07-11 |
| Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors (NCT03583086) | Vanderbilt-Ingram Cancer Center | 2018-07-10 |
| [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR) (NCT03724253) | Advanced Accelerator Applications | 2018-07-03 |
| Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer (NCT03585998) | Samsung Medical Center | 2018-06-19 |
| Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung Cancer (NCT03613597) | Guizhou Medical University | 2018-06-01 |
| Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer (NCT03613753) | ShengFa Su | 2018-06-01 |
| A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer (NCT03547804) | The First Hospital of Jilin University | 2018-05-31 |
| Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer (NCT03088813) | Ipsen | 2018-04-25 |
| SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy (NCT03417895) | Jiangsu HengRui Medicine Co., Ltd. | 2018-04-20 |
| NK Cell-based Immunotherapy as Maintenance Therapy for Small-Cell Lung Cancer. (NCT03410368) | jiuwei cui | 2018-04-01 |
| Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer (NCT03334487) | AbbVie | 2018-03-15 |
| Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) (NCT03406715) | H. Lee Moffitt Cancer Center and Research Institute | 2018-03-15 |
| Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases (NCT03391362) | Brigham and Women's Hospital | 2018-02-23 |
| PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (NCT03365791) | Novartis Pharmaceuticals | 2018-01-24 |
| Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer (NCT03371979) | Aeglea Biotherapeutics | 2017-12-21 |
| AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3] (NCT03366675) | Samsung Medical Center | 2017-12-01 |
| Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer (NCT03389087) | Henan Cancer Hospital | 2017-11-29 |
| Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer (NCT03325816) | Georgetown University | 2017-11-20 |
| Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer (NCT03216343) | Chipscreen Biosciences, Ltd. | 2017-11-09 |
| PEN-866 in Patients With Advanced Solid Malignancies (NCT03221400) | Tarveda Therapeutics | 2017-08-29 |
| A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms (NCT03219268) | MacroGenics | 2017-08-18 |
| Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification (NCT03106155) | Samsung Medical Center | 2017-08-02 |
| Simultaneous Integrated Boost vs. Routine IMRT in Limited-stage Small-cell Lung Cancer (NCT04500145) | Chinese Academy of Medical Sciences | 2017-07-20 |
| Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC (NCT03041311) | G1 Therapeutics, Inc. | 2017-06-29 |
| TS Overexpression in SCLC: Mechanism and Therapeutic Targeting (NCT03741829) | Wake Forest University Health Sciences | 2017-06-14 |
| Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases (NCT02978404) | Centre hospitalier de l'Université de Montréal (CHUM) | 2017-06-02 |
| Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer (NCT03098030) | United Therapeutics | 2017-06-01 |
| Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) (NCT03116971) | EMD Serono Research & Development Institute, Inc. | 2017-05-25 |
| Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer (NCT02963090) | Alliance Foundation Trials, LLC. | 2017-05-20 |
| Molecular Profiling in Small Cell Lung Cancer (NCT03162705) | Zhujiang Hospital | 2017-05-03 |
| A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer (NCT03086239) | AbbVie | 2017-04-28 |
| Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) (NCT03061812) | AbbVie | 2017-04-11 |
| A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer (NCT03026166) | AbbVie | 2017-03-30 |
| Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202) (NCT03059797) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-03-27 |
| STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC) (NCT02722369) | University College, London | 2017-03-14 |
| Immunotherapy as Second-line in Patient With Small Cell Lung Cancer (NCT03059667) | Intergroupe Francophone de Cancerologie Thoracique | 2017-03-13 |
| Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor (NCT03093688) | Shanghai Public Health Clinical Center | 2017-03-01 |
| A Study Evaluating MM-310 in Patients With Solid Tumors (NCT03076372) | Merrimack Pharmaceuticals | 2017-02-22 |
| Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer (NCT03043599) | H. Lee Moffitt Cancer Center and Research Institute | 2017-02-13 |
| A Study of APG-1252 in Patients With SCLC or Other Solid Tumors (NCT03080311) | Ascentage Pharma Group Inc. | 2017-02-12 |
| A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) (NCT03033511) | AbbVie | 2017-02-07 |
| Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC (NCT03219762) | Gruppo Oncologico Italiano di Ricerca Clinica | 2017-02-07 |
| A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients (NCT02661100) | Case Comprehensive Cancer Center | 2017-01-01 |
| A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC) (NCT02913443) | Hoffmann-La Roche | 2016-12-20 |
| Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC) (NCT02995187) | Chinese Academy of Medical Sciences | 2016-12-01 |
| Study of BMS-986012 in Subjects With Small Cell Lung Caner (NCT02949895) | Bristol-Myers Squibb | 2016-11-29 |
| Trial of BMS-986012 in Combination With Platinum and Etoposide (NCT02815592) | Bristol-Myers Squibb | 2016-11-28 |
| Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy. (NCT02945852) | Fan Yun, MD | 2016-10-01 |
| A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer (NCT02819999) | AbbVie | 2016-10-01 |
| Memory and MRI Changes With Hippocampus Avoidance Prophylactic Cranial Irradiation(HA-PCI) for Small Cell Lung Cancer(SCLC) (NCT02906384) | Zhejiang Cancer Hospital | 2016-10-01 |
| Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin (NCT02875457) | Third Military Medical University | 2016-09-01 |
| Development and Validation of Nomogram Predicting Survival in Chinese SCLC Patients (NCT05673798) | The Second Hospital of Shandong University | 2016-09-01 |
| Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (NCT02566993) | PharmaMar | 2016-08-30 |
| Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations (NCT03009682) | Samsung Medical Center | 2016-08-01 |
| Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation (NCT02688907) | Samsung Medical Center | 2016-06-07 |
| A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer (NCT02735980) | Eli Lilly and Company | 2016-05-11 |
| Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer (NCT02769962) | National Cancer Institute (NCI) | 2016-05-09 |
| NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer (NCT02425072) | John Villano | 2016-04-01 |
| LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies (NCT02649673) | SCRI Development Innovations, LLC | 2016-03-23 |
| Transformation Into Small Cell Lung Cancer : a Mode of Resistance to Treatment (NCT03419286) | University Hospital, Grenoble | 2016-02-01 |
| Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (NCT02674568) | AbbVie | 2016-01-25 |
| SBRT Compared With IMRT Concurrently With Chemotherapy in Treating Patients With LS-SCLC (NCT02738723) | Third Military Medical University | 2016-01-01 |
| Molecular Analysis and Treatment Options of SCLC (NCT05945745) | Shanghai Chest Hospital | 2016-01-01 |
| Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease (NCT02046733) | ETOP IBCSG Partners Foundation | 2015-12-18 |
| Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients (NCT02593019) | Samsung Medical Center | 2015-12-01 |
| Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients (NCT02622581) | AIO-Studien-gGmbH | 2015-12-01 |
| Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy (NCT02446704) | Zofia Piotrowska | 2015-10-13 |
| Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy (NCT02514447) | G1 Therapeutics, Inc. | 2015-10-05 |
| Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer (NCT02605811) | Guangzhou Medical University | 2015-09-01 |
| Abscopal Effect for Metastatic Small Cell Lung Cancer (NCT02542137) | Zhejiang Provincial People's Hospital | 2015-09-01 |
| Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC (NCT02577627) | Optimata Ltd. | 2015-09-01 |